Search
Results: 8
Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model.
Chiara Fornari, Lenka Oplustil O'Connor, Carmen Pin, Aaron Smith, James WT Yates, SY Amy Cheung, Duncan I Jodrell, Jerome T Mettetal, Teresa A Collins
Feb 06, 2020
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using observations in rat bone marrow and...
Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours
A Lindsay Frazier, Sara Stoneham, Carlos Rodriguez-Galindo, Ha Dang, Caihong Xia, Thomas A Olson, Matthew J Murray, James F Amatruda, Furqan Shaikh, Farzana Pashankar, Deborah Billmire, Mark Krailo, Dan Stark, Mark FH Brougham, James C Nicholson, Juliet P Hale
Feb 15, 2019
PURPOSE: To compare the outcomes of paediatric and adolescent extracranial malignant germ cell tumour (GCT) patients treated with either carboplatin or cisplatin on clinical trials conducted by the Children's Oncology Group...
Carboplatin cisplatin germ cell tumor testicular cancer Adolescent Adult Antineoplastic Combined Chemotherapy Protocols Australia Canada Carboplatin Child cisplatin Clinical Trials as Topic Female Humans Male Neoplasms Germ Cell and Embryonal Ovarian Neoplasms Progression-Free Survival Testicular Neoplasms United Kingdom United States Young Adult
Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
Rachana Shah, Caihong Xia, Mark Krailo, James F Amatruda, Suren G Arul, Deborah F Billmire, William E Brady, Allan Covens, David M Gershenson, Juliet P Hale, Jean Hurteau, Matthew J Murray, James C Nicholson, Thomas A Olson, Farzana Pashankar, Carlos Rodriguez-Galindo, Furqan Shaikh, Daniel Stark, A Lindsay Frazier, Sara Stoneham
Feb 15, 2019
OBJECTIVE: Dysgerminoma is the most common malignant ovarian germ cell tumor (GCT) with peak incidence during adolescence and young adulthood. Current standard of care for patients with disease that has spread outside of the...
Advanced-stage dysgerminoma Malignant germ cell tumor international consortium (MaGIC) Malignant ovarian germ cell tumor (MOGCT) Pediatric adolescent and young adult (AYA) Adolescent Adult Antineoplastic Combined Chemotherapy Protocols Carboplatin Child cisplatin Clinical Trials as Topic Dysgerminoma Female Humans Neoplasm Staging Neoplasms Germ Cell and Embryonal Ovarian Neoplasms Prognosis Young Adult
Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic.
Matthew J Murray, Rafael Moleron, Jennifer Adamski, Martin English, GA Amos Burke, Justin Cross, Thankamma Ajithkumar, Sara Stoneham, James C Nicholson
Sep 07, 2021
BACKGROUND: Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g....
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.
Ionut-Gabriel Funingana, Jacob S Bedia, Ying-Wen Huang, Antonio Delgado Gonzalez, Kenyi Donoso, Veronica D Gonzalez, James D Brenton, Alan Ashworth, Wendy J Fantl
Feb 28, 2023
New Model for Estimating Glomerular Filtration Rate in Patients With Cancer
T Janowitz, EH Williams, A Marshall, N Ainsworth, PB Thomas, SJ Sammut, S Shepherd, J White, PB Mark, AG Lynch, DI Jodrell, S Tavaré, H Earl
Aug 29, 2017
Purpose The glomerular filtration rate (GFR) is essential for carboplatin chemotherapy dosing; however, the best method to estimate GFR in patients with cancer is unknown. We identify the most accurate and least biased method....
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D Roman, Sarah P Blagden, Susana Banerjee, William P McGuire, Sharad Ghamande, Michael J Birrer, Gini F Fleming, Merry Jennifer Markham, Hal W Hirte, Diane M Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D Hall, Kenneth P Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Dec 19, 2019
PURPOSE: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial...
Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols Azacitidine Carboplatin Deoxycytidine Doxorubicin Drug Resistance Neoplasm Epigenesis Genetic Female Humans Middle Aged Neoplasm Recurrence Local Ovarian Neoplasms Paclitaxel Patient Safety Polyethylene Glycols Survival Rate Topotecan Treatment Outcome Gemcitabine
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Ruthenium complexes offer the potential of reduced toxicity, a novel mechanism of action, non-cross resistance and a different spectrum of activity compared to platinum containing compounds. Thirteen novel ruthenium(II)...
ATP Binding Cassette Transporter Subfamily B Member 1 Animals Antimetabolites Antineoplastic Antineoplastic Agents Azacitidine Calcium Channel Blockers Carboplatin cisplatin Decitabine Drug Design Drug Resistance Multiple Drug Resistance Neoplasm Drug Screening Assays Antitumor Edetic Acid Female Humans Ligands Mice Mice Nude Neoplasm Proteins Organometallic Compounds Ovarian Neoplasms Ruthenium Compounds Structure-Activity Relationship Verapamil Xenograft Model Antitumor Assays